GlassScriptPhysician profile
Michael Moskowitz
NPI 1144457938
$51,808.29
in general payments reported to CMS, 2019-2025
32 companies · $2,956 in 2025
The $2,956 reported for 2025 was more than what 98% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $677 · 2020: $9,958 · 2021: $14K · 2022: $22K · 2023: $828 · 2024: $1,282 · 2025: $2,956.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,377 · Consulting Fee: $1,664 · Education: $25.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,377.08 |
| Consulting Fee | $1,664.00 |
| Education | $25.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $45,442.57 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Regeneron Healthcare Solutions, INC. | $1,664.00 | 2025 | Dupixent |
| Medtronic, INC. | $1,260.00 | 2022 | |
| Lilly USA, LLC | $674.94 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $278.00 | 2023-2025 | |
| Abbott Laboratories | $245.02 | 2019-2023 | Freestyle Libre 3 |
| Amarin Pharma, INC. | $242.24 | 2019-2021 | |
| Amgen INC. | $219.33 | 2021-2024 | Repatha, Otezla |
| Abbvie INC. | $212.09 | 2020-2025 | |
| Glaxosmithkline, LLC. | $197.26 | 2022-2025 | Shingrix, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $159.89 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $155.32 | 2019-2025 | Airsupra, Farxiga |
| Merck Sharp & Dohme LLC | $150.60 | 2019-2025 | Gardasil 9, Capvaxive, Gardasil |
| Intuitive Surgical, INC. | $120.00 | 2025 | |
| Novartis Pharmaceuticals Corporation | $104.76 | 2021-2025 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $77.65 | 2025 | Injectafer |
| Aimmune Therapeutics, INC. | $72.88 | 2024 | |
| Exact Sciences Corporation | $65.28 | 2024-2025 | Cologuard Collection Kit |
| Eisai INC. | $58.46 | 2024-2025 | |
| Seqirus USA INC | $51.00 | 2019 | |
| Pfizer INC. | $44.09 | 2025 | |
| Currax Pharmaceuticals LLC | $40.74 | 2023-2024 | Nexletol, Contrave |
| Dynavax Technologies Corporation | $40.32 | 2024-2025 | Heplisav-B |
| Kestra Medical Technology Services, INC. | $37.96 | 2024 | Assure Wcd |
| Sanofi Pasteur INC. | $35.16 | 2019-2020 | |
| Renalytix Ai, INC. | $34.89 | 2024 | Kidneyintelx Blood Collection Convenience Kit |
| Takeda Pharmaceuticals U.S.A., INC. | $26.63 | 2025 | Entyvio |
| Ionis Pharmaceuticals, INC. | $24.87 | 2025 | Tryngolza |
| Esperion Therapeutics, INC. | $21.39 | 2024 | Nexletol |
| Amneal Pharmaceuticals LLC | $19.52 | 2025 | Unithroid |
| Intra-Sana Laboratories | $16.10 | 2025 | Glycate, Reltone 200 Mg, Reltone 400 Mg |
| Janssen Biotech, INC. | $15.33 | 2025 | Tremfya |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Moskowitz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
The CSV has this whole record: totals, yearly figures, every listed company, payment types, and product associations.
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.